PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
Phase 1
- Conditions
- Solid Tumor, AdultAdvanced Cancer
- Interventions
- Biological: PD-1 antibody expressing mesothelin specific CAR-T cells
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03030001
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer
Phase 1
- Conditions
- Precision Cell ImmunotherapyChemotherapyAdvanced Lung Cancer
- Interventions
- Drug: ChemotherapyBiological: Precision Cells
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02873416
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
Phase 1
- Conditions
- CAR-T CellsAdvanced MalignanciesPD-1 Antibody
- Interventions
- Biological: HerinCAR-PD1 cells
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02873390
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Phase 1
- Conditions
- ChemotherapyPrecision Cell ImmunotherapyAdvanced Gastric Cancer
- Interventions
- Drug: ChemotherapyBiological: Precision Cell Immunotherapy
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02873520
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Phase 1
- Conditions
- Advanced Liver CancerTranscatheter Arterial ChemoembolizationPrecision Cell Immunotherapy
- Interventions
- Procedure: TACEBiological: Precision Cells
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02873442
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath